Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...3233343536373839404142...136137»
  • ||||||||||  Is Subxiphoid Uniportal Video-Assisted Thoracoscopic Mediastinal Surgery Safe, Minimally Invasive, and Radical? (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1869;    
    It was considered necessary to discuss further expansion of indications in the future by taking into account safety and medium- to long-term result. Subxiphoid uniVATS might be a safe and less invasive procedure for anterior mediastinal tumors and MG, however, it is important to improve surgical techniques, anticipate intraoperative problems, and deal with them appropriately.
  • ||||||||||  Mixed Feelings about Mixed Thymomas (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1865;    
    Furthermore, this study showed that 43.8% of mixed thymomas had type B3-compartments. Patients with mixed-B3 thymoma underwent significantly less PORT after complete resection compared to non-mixed B3 thymoma.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    clinical and theurapeutic features in aquaporin-4 igg seropositive neuromyelitis optica spectrum disorders: a multicenter study of a greek patient cohort (Gold) -  Jul 21, 2023 - Abstract #MSMilan2023MSMilan_379;    
    Regarding acute phase treatments, all patients initially received high doses of intravenous (iv) methylprednisolone, and followingly 9 received iv immunoglobulin (IVIG), 9 plasma exchange (PLEX) and 3 combined treatments with IVIG and PLEX. In our seropositive NMOSD cohort, PLEX in the acute phase, rituximab and the add-on of oral glucocorticoids as prophylaxis were associated with better clinical outcomes and are in line with current literature; however, real-world data including the newly approved therapies for NMOSD should also be evaluated in future studies.
  • ||||||||||  prednisone / Generic mfg.
    Retrospective data, Journal:  COVID-19 infection in myasthenia gravis: Clinical course and outcomes. (Pubmed Central) -  Jul 21, 2023   
    Some patients with MG and COVID-19 also had an exacerbation during infection. Further studies are needed to determine whether MG patients are at higher risk for complications than the rest of the population.
  • ||||||||||  Observational data, Journal:  Exploring impairments and allied health professional utilisation in people with myasthenia gravis: A cross-sectional study. (Pubmed Central) -  Jul 21, 2023   
    Perception and utilisation of allied health professionals was variable; common barriers to better utilisation included participant perception of clinicians having poor knowledge around myasthenia gravis, previous poor experiences with clinicians, uncertainty about the clinicians' role, and lack of awareness that symptoms were associated with myasthenia gravis. Further research exploring clinicians' knowledge of myasthenia gravis is recommended, along with education for people with the disease about symptoms associated and how to appropriately access care.
  • ||||||||||  apraclonidine / Generic mfg.
    Retrospective data, Journal:  Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial. (Pubmed Central) -  Jul 21, 2023   
    P2
    Further research exploring clinicians' knowledge of myasthenia gravis is recommended, along with education for people with the disease about symptoms associated and how to appropriately access care. Apraclonidine may alleviate ptosis secondary to MG and may be an effective alternative treatment for this group of patients.
  • ||||||||||  Bridion (sugammadex) / Merck (MSD)
    Turn Your Iphone Into A Quantitative Neuromuscular Monitor (South: Hall D-7) -  Jul 20, 2023 - Abstract #ASA2023ASA_3146;    
    Your resident asks why not giving a larger dose of sugammadex to enhance reversal?7) Your resident found it cumbersome to secure iPhone to the patient's hand for TOF monitoring. He asks if there is any commercially available and easy-to-use quantitative neuromuscular monitor available.8) What is the ASA
  • ||||||||||  Bridion (sugammadex) / Merck (MSD)
    Turn Your Iphone Into A Quantitative Neuromuscular Monitor (South: Hall D-7) -  Jul 20, 2023 - Abstract #ASA2023ASA_1540;    
    Your resident asks why not giving a larger dose of sugammadex to enhance reversal?7) Your resident found it cumbersome to secure iPhone to the patient's hand for TOF monitoring. He asks if there is any commercially available and easy-to-use quantitative neuromuscular monitor available.8) What is the ASA
  • ||||||||||  Journal:  Transient Neonatal Myasthenia Gravis: A Case Report. (Pubmed Central) -  Jul 20, 2023   
    Adequate management of the newborn resulted in a positive outcome and evident withdrawal of the symptoms. Although TNMG is one of the rare neuromuscular disorders in newborns that can be treated, a multidisciplinary approach in the management of pregnant women with MG and newborns through timely diagnosis and early appropriate treatment, results in successful resolution of this condition.
  • ||||||||||  Journal:  Botulism due to Injection Drug Use. (Pubmed Central) -  Jul 19, 2023   
    We encourage readers to utilize a standardized patient to demonstrate extraocular muscle weakness and bulbar symptoms to increase psychological buy-in. Medical simulation, botulism, toxicologic emergencies, toxicology, neurology, emergency medicine.
  • ||||||||||  Journal:  Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good? (Pubmed Central) -  Jul 17, 2023   
    The population PK/PD model quantitatively described the relationships among tacrolimus dose, exposure and therapeutic efficacy in MG patients, which could provide reference for the optimization of tacrolimus dosing regimen at the individual patient level. No abstract available
  • ||||||||||  Journal:  LEMS: Clinical Significance of Pathogenic Autoantibodies (Pubmed Central) -  Jul 15, 2023   
    We comprehensively reviewed the MG/LEMS 2022 practice guidelines. Moreover, we presented a case of PCD without LEMS that was positive for P/Q-type VGCCs antibodies_and discussed the clinical significance of the autoantibodies.
  • ||||||||||  Journal:  Pathogenic Autoantibodies in Myasthenia Gravis (Pubmed Central) -  Jul 15, 2023   
    However, whether the Lrp4 antibody is pathogenic to MG is controversial because of its lack of disease specificity. This review focuses on the targets of these autoantibodies at the neuromuscular junction; the clinical significance of antibody positivity; and the differences in clinical presentation, treatment, and prognosis according to pathogenic autoantibodies.
  • ||||||||||  Journal:  Plus minus lid syndrome in Myasthenia gravis. (Pubmed Central) -  Jul 14, 2023   
    This review focuses on the targets of these autoantibodies at the neuromuscular junction; the clinical significance of antibody positivity; and the differences in clinical presentation, treatment, and prognosis according to pathogenic autoantibodies. No abstract available
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  SP Thoracic IDE Study (clinicaltrials.gov) -  Jul 12, 2023   
    P=N/A,  N=32, Active, not recruiting, 
    These data indicate that UCD-PNP patients belong to a subgroup sharing strong clinical and biological identity that might help to decipher the different dynamics of UCD natural history. Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> Jul 2028 | Trial primary completion date: Dec 2023 --> Jun 2023
  • ||||||||||  Journal:  A Digital Telehealth System to Compute the Myasthenia Gravis Core Examination Metrics. (Pubmed Central) -  Jul 12, 2023   
    Our results indicate that the MG-CE should be revisited to consider some of the new metrics that our algorithm identified. We provide a proof of concept involving the MG-CE, but the method and tools developed can be applied to many neurological disorders and have great potential to improve clinical care.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Eculizumab treatment alters the proteometabolome beyond the inhibiton of complement. (Pubmed Central) -  Jul 11, 2023   
    As eculizumab prevents cleavage of C5 into C5a, decreased engagement of C5aR may inhibit ALOX5-mediated synthesis of pro-inflammatory leukotrienes. These findings indicate distinct "off-target effects" induced by eculizumab, illuminating potential mechanisms of action that may be harnessed to improve treatment outcomes.
  • ||||||||||  Journal:  Galactosylation of serum immunoglobulin G in myasthenia gravis with different autoantibodies. (Pubmed Central) -  Jul 10, 2023   
    These findings indicate distinct "off-target effects" induced by eculizumab, illuminating potential mechanisms of action that may be harnessed to improve treatment outcomes. The average R values for mild disease (stages I-IIIa) were significantly lower than for severe disease (stages IIIb-V), both at the time of diagnosis (p
  • ||||||||||  Journal:  Outcomes after thymectomy in non-thymomatous myasthenia gravis. (Pubmed Central) -  Jul 10, 2023   
    Patients with NTMG undergoing thymectomy experienced less need for rescue therapy following resection, albeit with increased rates of steroid prescriptions. Thymectomy is infrequently performed in this patient population despite acceptable postsurgical outcomes.
  • ||||||||||  azathioprine / Generic mfg.
    Retrospective data, Journal:  The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan. (Pubmed Central) -  Jul 10, 2023   
    First-line treatment was with pyridostigmine (82%), steroids (58%), and azathioprine (11%)...The epidemiology of gMG in Taiwan is evolving rapidly, with higher prevalence rates and increasing involvement of older age-groups suggesting a growing burden of disease and associated healthcare costs. HBV infection or reactivation may pose a previously unrecognized recognized risk for patients with gMG receiving immunosuppressants.